
Oncology
How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC
For years, thoracic oncologists faced a frustrating therapeutic ceiling when treating non-small cell lung cancer (NSCLC) driven by
Rayan Salih · June 18, 2026 · 10 min




